Verapamil for Neuroprotection in Stroke

Description

The purpose of this research study is to test an experimental procedure called intra-arterial delivery of verapamil in patients diagnosed with acute ischemic stroke. This study investigates the safety of intra-arterial delivery of verapamil, a drug used to treat vasospasm (spasm of a blood vessel), and how it affects recovery from stroke. Recruitment is limited to patients that have received mechanical thrombectomy as standard of care.

Conditions

Ischemic Stroke

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this research study is to test an experimental procedure called intra-arterial delivery of verapamil in patients diagnosed with acute ischemic stroke. This study investigates the safety of intra-arterial delivery of verapamil, a drug used to treat vasospasm (spasm of a blood vessel), and how it affects recovery from stroke. Recruitment is limited to patients that have received mechanical thrombectomy as standard of care.

Intraarterial Verapamil for Neuroprotection in Ischemic Stroke

Verapamil for Neuroprotection in Stroke

Condition
Ischemic Stroke
Intervention / Treatment

-

Contacts and Locations

Atlantic City

AtlantiCare Regional Medical Center, Atlantic City, New Jersey, United States, 08401

Langhorne

St Mary Medical Center, Langhorne, Pennsylvania, United States, 19047

Upland

Crozer Chester Medical Center, Upland, Pennsylvania, United States, 19013

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Written informed consent
  • * 18 years of age and over
  • * Acute onset focal neurologic deficit consistent with acute ischemic stroke, or computed tomographic scan consistent with acute cerebral ischemia
  • * Candidate for mechanical thrombectomy procedure
  • * Onset of symptoms less than 8 hours
  • * Measurable neurologic deficit (NIHSS ≥4)
  • * Willingness to follow up with rehabilitation therapy
  • * Anticipated life expectancy of at least 3 months
  • * Pregnancy or suspected pregnancy (pregnancy test will be done on women of child-bearing potential)
  • * Hepatic and/or renal insufficiency (LFT's\>3× upper limit of normal; CrCl \< 30ml/min)
  • * Thrombocytopenia (platelet count \<75,000/mm3)
  • * History of intolerance to verapamil
  • * Previous functional disability (modified Rankin \> 1)
  • * Severe stroke (NIHSS\>22)
  • * Stuporous or comatose
  • * Unlikely to be available for 90 day follow-up

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Global Neurosciences Institute,

Study Record Dates

2026-12